#### **BIOMARIN PHARMACEUTICAL INC**

Form 4 March 20, 2008

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

**OMB APPROVAL** 

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction 1(b).

(Print or Type Responses)

	•								
1. Name and Address of Reporting Person * BAFFI ROBERT							5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)		
(Last)  C/O BIOM PHARMA DIGITAL	IARIN CEUTICAL INC.	(Mont 03/18					Director 10% Owner _X_ Officer (give title Other (specify below)  SVP, Technical Operations		
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)  NOVATO, CA 94949				- -	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	able I - Non-D	erivative	Secur	ities Acqui	ired, Disposed of	, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		f Transaction Code r) (Instr. 8)		ed of (	(D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/18/2008(1)	03/18/2008		46,240	A	\$ 12.1	80,920	D	
Common Stock	03/18/2008(1)	03/18/2008	S	200	D	\$ 31.76	80,720	D	
Common Stock	03/18/2008(1)	03/18/2008	S	100	D	\$ 31.85	80,620	D	
Common Stock	03/18/2008(1)	03/18/2008	S	700	D	\$ 31.86	79,920	D	
	03/18/2008(1)	03/18/2008	S	700	D	\$ 31.88	79,220	D	

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock							
Common Stock	03/18/2008(1)	03/18/2008	S	100	D	\$ 31.92 79,120	D
Common Stock	03/18/2008(1)	03/18/2008	S	300	D	\$ 31.95 78,820	D
Common Stock	03/18/2008(1)	03/18/2008	S	100	D	\$ 31.96 78,720	D
Common Stock	03/18/2008(1)	03/18/2008	S	555	D	\$ 31.98 78,165	D
Common Stock	03/18/2008(1)	03/18/2008	S	11	D	\$ 31.99 78,154	D
Common Stock	03/18/2008(1)	03/18/2008	S	89	D	\$ 32 78,065	D
Common Stock	03/18/2008(1)	03/18/2008	S	100	D	\$ 32.01 77,965	D
Common Stock	03/18/2008(1)	03/18/2008	S	245	D	\$ 32.08 77,720	D
Common Stock	03/18/2008(1)	03/18/2008	S	100	D	\$ 77,620 32.088	D
Common Stock	03/18/2008(1)	03/18/2008	S	200	D	\$ 32.09 77,420	D
Common Stock	03/18/2008(1)	03/18/2008	S	1,240	D	\$ 32.1 76,180	D
Common Stock	03/18/2008(1)	03/18/2008	S	700	D	\$ 32.12 75,480	D
Common Stock	03/18/2008(1)	03/18/2008	S	200	D	\$ 32.14 75,280	D
Common Stock	03/18/2008(1)	03/18/2008	S	88	D	\$ 32.15 75,192	D
Common Stock	03/18/2008(1)	03/18/2008	S	100	D	\$ 75,092	D
Common Stock	03/18/2008(1)	03/18/2008	S	300	D	\$ 32.19 74,792	D
Common Stock	03/18/2008(1)	03/18/2008	S	100	D	\$ 32.2 74,692	D
Common Stock	03/18/2008(1)	03/18/2008	S	600	D	\$ 32.21 74,092	D
Common Stock	03/18/2008(1)	03/18/2008	S	100	D	\$ 32.22 73,992	D
	03/18/2008(1)	03/18/2008	S	600	D	\$ 32.23 73,392	D

### Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock							
Common Stock	03/18/2008(1)	03/18/2008	S	800	D	\$ 32.24 72,592	D
Common Stock	03/18/2008(1)	03/18/2008	S	2,400	D	\$ 32.25 70,192	D
Common Stock	03/18/2008(1)	03/18/2008	S	700	D	\$ 32.28 69,492	D
Common Stock	03/18/2008(1)	03/18/2008	S	200	D	\$ 32.29 69,292	D
Common Stock	03/18/2008(1)	03/18/2008	S	500	D	\$ 32.3 68,792	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (right to buy)	\$ 12.1	03/18/2008(1)	03/18/2008	M	41,240	07/01/2002(2)	12/31/2011	Common Stock	41,240
Stock Option (right to	\$ 12.1	03/18/2008(1)	03/18/2008	M	5,000	04/01/2002(3)	12/31/2011	Common Stock	5,000

# **Reporting Owners**

buy)

Reporting Owner Name / Address			Relationships	
	Director	10% Owner	Officer	Other

Reporting Owners 3

### Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

BAFFI ROBERT C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949

SVP, Technical Operations

## **Signatures**

/s/ G. Eric Davis, Attorney-in-Fact

03/20/2008

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 Trading Plan.
- (2) Original option grant vested 6/48ths on 7/1/02, and 1/48th on the 1st of every month thereafter.
- (3) Original option grant vested 1/4 each on 4/1/2002, 7/1/2002, 10/1/2002 and 1/1/2003.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 4